Neutropenia Treatment Market Size - By Treatment Type (CSF, Antibiotics, Antifungal, Antiviral), Drug Type (Branded, Biosimilar), Route of Administration, Indication (Chemotherapy-induced, Cyclic, Congenital), Distribution Channel, Global Forecast, 2024 – 2032

Neutropenia Treatment Market Size

Neutropenia Treatment Market was valued at USD 14.5 billion in 2023 and is set to grow at over 4.1% CAGR from 2024 to 2032, driven by the increasing prevalence of neutropenia, marked by abnormally low neutrophil levels which intensified the demand for neutropenia treatment. Additionally, the rising incidence of disorders like cancer and autoimmune diseases, leading to neutropenia, further fuelled the demand for effective treatment, contributing to market growth.
 

Neutropenia treatment refers to the therapeutic interventions to manage and alleviate the condition characterized by abnormally low levels of neutrophils, a type of white blood cell crucial for the body's immune response. The treatment approaches involve addressing the underlying cause of neutropenia, such as chemotherapy-induced myelosuppression function, autoimmune disorders, or congenital conditions.
 

Neutropenia Treatment Market Trends

Rising utilization of chemotherapy, a widely employed therapy for diverse cancers, propelled by the increasing incidence of cancer is influencing the market growth. Chemotherapy frequently results in diminished neutrophil levels, necessitating efficient neutropenia treatments, thus stimulating market demand. However, the introduction of biosimilars has significantly impacted the market by offering a more cost-effective alternative to original brands. This has led to increased competition, pricing disparities, and potential market saturation, thereby hampering the overall market growth.
 

Neutropenia Treatment Market Analysis

Based on the treatment type, the global neutropenia treatment industry is categorized into colony-stimulating factors (CSFs), antibiotics, antifungals, antivirals, and other treatment types. The CSF segment is expected to reach USD 13 billion by 2032.
 

• The dominance of CSF, particularly granulocyte colony-stimulating factor (G-CSF), stemmed from its ability to stimulate the production of white blood cells, specifically neutrophils, which are crucial for combating infections. Therefore, neutrophils play a vital role in the body's defense against infections.
   
• Depletion of neutrophils, often caused by chemotherapy, can result in neutropenia—a condition marked by dangerously low neutrophil counts. G-CSF acts by stimulating the production of white blood cells, particularly neutrophils in the bone marrow. This therapy aids in replenishing neutrophil levels, thereby reducing the risk of infections and associated complications in patients undergoing chemotherapy or other treatments that suppress the immune system. Thus, its efficacy in managing neutropenia has propelled its widespread adoption and dominance in the market.

Based on drug type, the market is classified into branded and biosimilars. The branded drugs type segment is anticipated to secure the largest market share of 58.2% in 2023.
 

• Branded neutropenia drugs have asserted dominance in the neutropenia treatment market, holding a significant share due to their established reputation, efficacy, and widespread recognition among healthcare providers and patients.
   
• Moreover, the biosimilars drugs provide comparable efficacy and safety profiles at reduced costs. This growth trajectory is attributed to factors like patent expirations, cost constraints, and favorable regulatory frameworks. Thus, owing to such aforementioned factors, the segment is expected to exhibit substantial expansion during the analysis, serving as bioequivalent alternatives to original drugs.
   

Based on the route of administration, the market is classified into oral and parenteral routes. Parenteral route segment dominated the market accounting for over USD 9.5 billion in 2023.
 

• The parenteral route has emerged as the predominant method as it indicates the treatment administered subcutaneously or intravenously bypassing the digestive system. The factors attributing to the choice are the rapid onset of action, precise dosing, and high bioavailability. Also, for neutropenia treatment, parenteral administration ensures the timely delivery of medications to the bloodstream, enabling effective management of neutrophil levels and reducing the risk of infections.
   
• Thus, the aforementioned factors highlighted the effectiveness and preference for parenteral therapies in addressing neutropenia-related conditions, thereby augmenting the segmental growth.
   

Based on indication, the neutropenia treatment market is classified into chemotherapy-induced neutropenia, cyclic neutropenia, idiopathic neutropenia, and congenital neutropenia. The chemotherapy-induced neutropenia segment is anticipated to exhibit about 3.8% growth rate through 2032.
 

• Cancer ranks as the second leading global cause of death, with around 1 in 6 deaths, it presents a significant global challenge. For instance, in Australia, over 151,000 new cancer cases were estimated in 2021. Also, research estimates indicated that 50% of chemotherapy recipients anticipate developing neutropenia. Therefore, the increase in cancer cases and the widespread use of chemotherapy linked to decreased neutrophil levels, have led to the dominance of chemotherapy-induced neutropenia in the market.
   

Based on the distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies segment dominated nearly 48.3% market share in 2023.
 

• The dominance of hospital pharmacies in the neutropenia treatment market stems from their crucial role in providing specialized medications for patients undergoing neutropenia condition treatments. The pharmacies ensure timely access to neutropenia treatments, including CSF and supportive care medications, optimizing patient care and outcomes.
   
• Additionally, hospital pharmacies often collaborate closely with oncologists and other healthcare providers to customize treatment regimens according to individual patient needs, further solidifying their dominance in the market.

North America neutropenia treatment market size to surpass USD 7.4 billion by 2032.
 

• North America is poised to hold a significant market share due to factors like increasing cancer prevalence, demand for disease-specific treatment, robust healthcare spending, well-established infrastructure, and the presence of key market players.
   
• In addition, the growing emphasis of companies on developing advanced and effective therapies for neutropenia treatment, coupled with increasing drug approvals, significantly contributes to market growth. For instance, in April 2022, Spectrum Pharmaceuticals resubmitted Biologics License Application (BLA) for eflapegrastim. The company gained acceptance from the U.S. Food and Drug Administration (FDA) for treating chemotherapy-induced neutropenia, further driving market expansion. Thus, the persistent research activities aimed at addressing patient needs and devising efficient treatment solutions is expected to spur the market expansion.
   

Neutropenia Treatment Market Share

The neutropenia treatment industry is characterized by intense competition among key players striving to innovate and develop effective treatments to cater to the patient needs with neutropenia. Major pharmaceutical and biotechnology companies are focusing on key strategies employed including product innovation, strategic partnerships, mergers and acquisitions, and geographical expansions to gain a competitive edge.
 

Neutropenia Treatment Market Companies

Prominent players operating in the neutropenia treatment industry are as mentioned below:

• Amgen Inc.
• BeyondSpring Inc.
• Biocon Biologics Inc.
• Cellerant Therapeutics
• Coherus BioSciences, Inc.
• CuraTeQ Biologics Pvt. Ltd.
• Evive Biotech
• Kyowa Kirin Co., Ltd.
• Pfizer Inc.
• Sandoz Inc.
• Spectrum Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
   

Neutropenia Treatment Industry News

• In December 2023, Coherus BioSciences, Inc. received FDA approval for its on-body injector (OBI) version of the biosimilar pegfilgrastim-cbqv -Udencya, named Udencya Onbody. It is recommended to cancer patient’s post-chemotherapy to reduce febrile neutropenia risk. The launch intended to introduce a new, proprietary device offering patients automated medication delivery, thereby strengthening its business portfolio.
   
• In November 2023, Evive Biotech and Acrotech Biopharma obtained FDA approval for Ryzneuta, aimed at reducing infection rates, specifically febrile neutropenia, in adults with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatment. The launch addressed the demand for effective first-line and alternative therapies among cancer patients.
   

This neutropenia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Colony-stimulating factors (CSFs)
• Antibiotics
• Antifungals
• Antivirals
• Other treatment types

Market, By Drug Type

• Branded
• Biosimilars

Market, By Route of Administration

• Oral
• Parenteral

Market, By Indication

• Chemotherapy-induced neutropenia
• Cyclic neutropenia
• Idiopathic neutropenia
• Congenital neutropenia

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa